Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase IIb/III study of Aladote to reduce liver damage associated with paracetamol poisoning

Next Previous
Trial Profile

A pivotal Phase IIb/III study of Aladote to reduce liver damage associated with paracetamol poisoning

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 13 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calmangafodipir (Primary)
  • Indications Drug toxicity; Liver injury
  • Focus Registrational; Therapeutic Use
  • Acronyms Albatross
  • Sponsors Egetis Therapeutics

Most Recent Events

  • 10 Oct 2023 According to an Egetis Therapeutics media release, company planned to start this study after Emcitate submissions have been completed.
  • 26 Apr 2023 According to an Egetis Therapeutics media release, the design of the pivotal Phase Iib/III study, which is called Albatross, has been agreed with the FDA, EMA and MHRA.
  • 27 Jan 2023 According to an Egetis Therapeutics media release, study is expected to initiate during 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top